Licensed Antibodies. Subject to (i) MorphoSys’ and/or its Affiliates’ existing (as of the Effective Date) HuCAL agreements, comprising any obligation for MorphoSys and/or its Affiliate(s) to generate or have generated antibodies to which MorphoSys’ and/or its Affiliates’ contract partners have any rights whatsoever, and (ii) any non-therapeutic, non-prophylactic activity of MorphoSys and/or its Affiliate(s), MorphoSys hereby covenants ***Confidential Treatment Requested that, during the Term, MorphoSys and its Affiliates shall not preclinically develop, develop in any human clinical trial, seek Market Authorization for, or in any way commercialize in the MorphoSys Territory any […***…] other than any Licensed Antibody and/or Licensed Products that are payment-bearing to Xencor under this Agreement (other than a Licensed Product for which the Royalty Term has expired, after such expiration; this covenant does not apply at such times to such Licensed Product). Sublicensees specifically do not make such covenant, and MorphoSys does not make such covenant as to Sublicensees.
Licensed Antibodies. The term "Licensed Antibodies" shall mean the antibodies set forth in Exhibit A hereto, and any subsequent monoclonal antibodies owned, licensed or developed by M-Tech or its Affiliates that are directed towards the same antigens as the antibodies listed in Exhibit A. Expressly excluded from the Licensed Antibodies are any subclone cell lines isolated from the [***] cell line other than those that primarily produce human monoclonal antibodies to [***], whether alone or in combination with other antigens.
Licensed Antibodies. (i) Subject to the terms and conditions of this Agreement, Kadmon hereby grants to Jinghua an exclusive license, with the right to grant sublicenses in accordance with Section 3.2, under the Intellectual Property Controlled by Kadmon as of the Effective Date, including the Kadmon Patents, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Products in the Territory. For the avoidance of doubt, to the extent a Third Party contributed to the Licensed Antibody, no such license shall be granted to the extent (1) Kadmon does not have the right to do so under its contractual relationship with such Third Party, or (2) if doing so causes Kadmon to incur any payment obligation to any Third Party.
Licensed Antibodies. With respect to each Licensed Antibody isolated by Licensee under the Library License granted to Licensee under Section 3.1(a) above, and subject to the terms and conditions of this Agreement (including without limitation, the restrictions set forth in Sections 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7 and the payment obligations set forth in Article 4), Dyax hereby grants to Licensee and its Affiliates:
Licensed Antibodies. Licensor has disclosed to EQRx all Antibodies that Licensor or any of its Affiliates owns or in-licenses, as of the Execution Date, that relate to the Licensed Antibodies.
